23 Oct 2009 ... Tysabri sales lift Elan revenues. Athlone-based pharmaceutical group Elan has
today reported net income of $52.3 million for its fiscal ...

www.topix.com/who/elan

1 Oct 2008 ... Maxipime: Official Site elan.com - Official Site · RxList: Maxipime Drug
Description rxlist.com ... Tysabri sales lift Elan revenues ...

organizedwisdom.com/Maxipime

22 Jul 2008 ... Elan hires Citigroup to review possible sale, merger or strategic alliance ...
Elan revenues in first quarter boosted by Tysabri MS drug; ...

www.finfacts.ie/irishfinancenews/article_1014260.shtml

In the United States , Elan purchases Tysabri from Biogen Idec and is
responsible for distribution. Consequently, Elan records as revenue the net
sales of ...

ir.elan.com/phoenix.zhtml?c=88326&p=irol-pressroomarticle&ID=1344354&high

31 Oct 2008 ... MS drug sales lift Elan Elan has seen revenue for the third quarter ... year has
contracted a life threatening illness after taking Tysabri, ...

prospect.rsc.org/blogs/cw/?p=1241

9 Feb 2010 ... Biogen and Elan Corp. PLC sell Tysabri through a partnership. Biogen said sales
rose to $216.2 million. Revenue from Avonex grew 5 percent ...

www.boston.com/business/ticker/2010/02/ms_drugs_help_l.html

UPDATE 1-Elan Q2 revenues up 14 percent on Tysabri sales. Tue, Jul 21 2009.
UPDATE 3-Biogen 2nd-qtr profit falls; Tysabri sales up. Thu, Jul 16 2009 ...

www.reuters.com/article/idUSTRE56K25120090721

6 Aug 2009 ... Elan Breached Tysabri Partnership With Biogen Idec, ... has pinned much of its
near-term revenue growth on increased sales of natalizumab. ...

www.xconomy.com/boston/2009/08/06/elan-hits-biogen-idec-with-lawsuit-to-p

28 Jun 2009 ... If Novartis was to buy the Tysabri and bapineuzumab parts of Elan, as suggested
in ... With less than $40 million in revenues per quarter remaining, ... Elan
Sees Problems on Alzheimer's Drug; Puts Itself Up for Sale ...

industry.bnet.com/pharma/10002896/if-novartis-buys-elans-tysabri-and-ms-d

21 Dec 2006 ... "Over the next 12 months, I think Elan's price will move up as Tysabri sales
accelerate in the U.S. and Europe. In addition, Elan just filed ...

www.bloggingstocks.com/2006/12/21/top-picks-2007-ken-kam-revisits-elan-an